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Abstract
Introduction: COPD is one of the most frequent respiratory diseases responsible for patients’ disability and mortality. In 2005 
a single primary care practice, COPD was diagnosed in 183 out of 1,960 eligible subjects ≥ 40 years (9.3%). The aim of this study 
was to assess mortality rate and causes of deaths in this group after 6 years.
Material and methods: In 2011 we invited all 183 patients with COPD recognised in 2005. We performed spirometry, physical 
examination, questionnaire of respiratory symptoms, smoking habits, concomitant diseases and treatment. Information about 
deaths was taken from primary care register, furthermore, family members were asked to deliver medical documentation or death 
certificate.
Results: In 2011 we studied only 74 subjects (40.4%), 43 subjects died (23.5%) and 66 subjects were lost from the follow-up 
(36.1%). Cardiovascular diseases were the most frequent causes of deaths — 21 subjects (48.8%) (heart attack – 8 patients 
and stroke – 8 patients). Respiratory failure in the course of COPD exacerbation was the cause of 10 deaths (23.3%). Neoplastic 
diseases lead to 9 deaths (20.9%) (lung cancer 7 patients). Renal insufficiency was responsible for one death (2.325%), and the 
causes of 2 deaths remained unknown (4.65%). Subjects who died (predominantly males) were older, had higher MRC score and 
lower FEV1. 
Conclusions: Study performed six years after COPD diagnosis revealed that 23.5% of subjects died. The main causes of deaths 
were the following: cardiovascular diseases (mainly heart attack and stroke), COPD exacerbations and lung cancer (more than 
75%). Death risk in COPD patients was associated with age, male sex, dyspnoea and severity of the disease. 
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Streszczenie
Wstęp: POChP jest jedną z najczęstszych chorób układu oddechowego, która prowadzi do inwalidztwa oddechowego oraz 
przedwczesnej śmierci. W 2005 roku w pojedynczej placówce podstawowej opieki zdrowotnej rozpoznano POChP u 183 spośród 
zbadanych 1960 osób, które ukończyły 40. rok życia (9,3%).
Celem pracy była analiza częstości zgonów i ich przyczyn w grupie chorych na POChP po 6 latach obserwacji. 
Materiał i metody: W 2011 roku na badania kontrolne zaproszono wszystkie 183 osoby, u których rozpoznano POChP w 2005 
roku. Badani wypełniali kwestionariusz dotyczący dolegliwości oddechowych, palenia tytoniu, chorób współistniejących oraz 
aktualnego leczenia. Po weryfikacji kwestionariusza wykonywano badanie przedmiotowe i spirometrię. Informację o śmierci 
pacjentów uzyskiwano z aktualnej kartoteki POZ oraz od rodzin badanych (na podstawie uzyskanej dokumentacji medycznej — 
ustalano datę i miejsce zgonu oraz jego przyczyny). 
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Wyniki: W 2011 roku zbadano tylko 74 chorych (40,4%), 43 chorych zmarło (23,5%). Pozostałych 66 chorych nie udało się 
zbadać ponownie (36,1%). Choroby układu krążenia były najczęstszymi przyczynami zgonów u chorych na POChP — 21 cho-
rych (48,8%) (w tym zawał serca — 8 chorych i udar mózgu — 8 chorych). Niewydolność oddychania w przebiegu POChP 
była przyczyną śmierci u 10 badanych (23,3%). Choroby nowotworowe były odpowiedzialne za 9 zgonów (20,9%) (rak płuc — 
7 chorych). Pozostałe zgony wiązały się z niewydolnością nerek (1 chory; 2,325%) oraz przyczynami nieustalonymi (2 chorych; 
4,65%). Chorzy na POChP, którzy zmarli (większość stanowili mężczyźni) byli starsi, mieli większe nasilenie duszności w skali 
MRC oraz niższe FEV1.
Wnioski: Badania kontrolne wykonane po 6 latach od rozpoznania choroby ujawniły wysoką umieralność w badanej grupie (zmar-
ło 43 chorych — 23,5%). Ponad 75% wszystkich zgonów było spowodowane chorobami układu krążenia (najczęściej zawałem 
serca i udarem mózgu), zaostrzeniami POChP i rakiem płuc. Czynnikami, które wpływały na wzrost ryzyka zgonu w badanej grupie, 
były: wiek, płeć męska, większe nasilenie duszności oraz cięższą postać choroby. 
Słowa kluczowe: śmiertelność, POChP, podstawowa opieka zdrowotna, epidemiologia, spirometria
Pneumonol Alergol Pol 2015; 83: 193–202
Introduction
Chronic obstructive pulmonary disease 
(COPD) is one of the most frequent chronic dis-
eases, significance of which is constantly growing. 
The frequent prevalence of the disease, cost-con-
suming treatment and rehabilitation (particularly 
hospitalisations due to exacerbations), conse-
quences such as chronic respiratory insufficiency 
(the necessity for using oxygen therapy at home 
or non-invasive assisted ventilation), concomitant 
diseases (more frequent in comparison to the 
general population), heart diseases, neoplasms 
and deaths in the course of COPD, all these fac-
tors make the illness not only a serious medical 
problem but also a social and economic issue. 
According to epidemiology data, lung diseas-
es (including COPD as the most frequent) in Po-
land are the fourth most often encountered cause 
of death after cardiovascular diseases, malignant 
neoplasms and unexpected sudden death [1]. 
The above observations are in accordance with 
worldwide trends, which in 1997 implied that 
unless smoking cigarettes becomes less popular, 
in 2020, COPD will be the third cause of death 
worldwide [2]. The Global Burden of Diseases, 
Injuries and Risk Factors Study disclosed that 
COPD was the third most frequent cause of deaths 
in 2010 (235 causes of deaths were evaluated in 21 
regions of the world, taking into account age and 
sex) [3]. Mortality from COPD in Europe between 
1994 — 2010 was assessed more optimistically 
[4]. In 27 countries of the European Union (EU) 
mortality from COPD decreased from 90.07 to 
61.33 per 100,000 population (2.56% percent of 
annual change — PAC) in men, and from 26.99 
to 25.15 per 100,000 population (0.76% PAC) in 
women (age-standardised mortality rates). The 
evaluation of mortality rate showed an upward 
trend in 5 countries of the EU for men and in 14 
countries for women. As far as Poland is con-
cerned, it confirmed a downward trend in men 
(by 0.34%, NS) and an upward trend in women 
(by 1.55%, p < 0.05).
The objective of the study was to analyse the 
frequency and causes of deaths in the group of 
COPD patients in a single primary care institution 
6 years after diagnosis of the disease. 
Material and methods
The study group included 183 patients with 
COPD diagnosed in 2005 in a single primary care 
institution in Sierpc (NZOZ Medicar) (9.3% of 
the study population of 1,960 individuals aged ≥ 
40 years) [5]. In 2011, the patients received let-
ters or calls inviting them to perform follow-up 
examination.
At the beginning of the appointment the pa-
tient was completing a questionnaire concerning 
the place of residence (city/village), occupational 
status (employee — place of work, retiree, pen-
sioner — the reason for a pension), economic 
status (in a subjective opinion of the respon-
dent: good, satisfying, bad), exposure to tobacco 
smoke (current and former smokers — subjects 
who ceased smoking at least 6 months prior to 
the examination, non-smokers; for the two first 
groups, the number of pack-years was evaluated), 
respiratory symptoms (the MRC dyspnoea scale), 
cough and expectoration of sputum (in the case 
of a positive answer to the question whether the 
above symptoms are chronic according to the 
definition of chronic bronchitis), the number of 
COPD exacerbations and hospitalisations (since 
the previous examination), concomitant diseases, 
current treatment. Afterwards physical examina-
tion was made including measurement of height 
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and body mass. Spirometry was performed us-
ing a portable spirometer (EasyOne Diagnostic, 
model 2001; NDD Medical Technologies, Zurich, 
Switzerland). 
The patients were seated during the pro-
cedure. Forced vital capacity (FVC) and forced 
expiratory volume in the first second (FEV1) were 
measured, and FEV1/FVC ratio was calculated. 
Spirometry was repeated unless three acceptable 
and repeatable blows were obtained [6]. After 
initial procedure, reversibility test was carried 
out (subsequent spirometry was performed 15 
minutes after administration of 400mcg of sal-
butamol).
The degree of obstruction in COPD patients 
was evaluated in accordance with the GOLD 
guidelines [7] using predicted values adopted by 
the ECSC (European Community for Steel and 
Coal) [8]. COPD category was classified basing on 
the severity of obstruction, MRC dyspnoea scale, 
a number of exacerbations per year (the subjects 
have not completed the COPD Assessment Test 
(CAT) [9, 10].
Information on patients’ deaths was obtained 
from medical documentation (medical death cer-
tificates), from doctors in charge (mainly when 
family physician was changed) from the patients’ 
family (they were asked to deliver all documen-
tation if there was no contact with the patient). 
Statistical analysis
Statistical calculations were made using 
the program Statistica 6.0. The values of quan-
titative variables were calculated as arithmetical 
mean and standard deviations. The groups were 
compared using analysis of variances. Fisher’s 
Anova test was used, provided there was normal 
distribution of the variable studied and homo-
geneity of variance. Post hoc analysis for groups 
with different numbers of subjects were made 
with the help of Sheffe and Tukey tests. If the 
distribution of the variables was not normal, and 
variance was not homogenous — non-parametric 
Kruskal-Wallis test was applied (the comparison 
of two or more groups). Differences between the 
groups were regarded statistically significant with 
p < 0.05. 
Comparisons between various groups of qual-
itative variables were performed using c2 Pearson’s 
test or its modifications (Yates’ and Fisher’s tests) 
for smaller groups.
Results
Among 183 patients (98 men — 53.6% and 85 
women — 46.4%) with COPD diagnosed in 2005, 
follow-up examination in 2011 was performed in 
74 subjects (40.4%), and information about death 
of 43 patients (23.5%) between 2005−2011 was 
obtained. The remaining subjects (66 people — 
36.1% of the initial group) have not undergone 
follow-up examination. 
In the group of 74 patients examined in 2011, 
a mean of age was 65.8 ± 9.7 years and BMI — 
27.2 ± 4.9 kg/m2. Men constituted 51.4% of the 
group (38 individuals), whereas women 48.6% 
(36 individuals). 40 subjects (54.1%) lived in the 
city and 34 (45.9%) in the country.
Acceptable and repeatable spirometry tests 
(category A and B) were obtained in 62 subjects 
(83.8%). The results of spirometry were presented 
in Table 1.
The severity of bronchial obstruction as-
sessed by spirometry in 2011 in the study group 
was as follows: mild (FEV1 ≥ 80% predicted) — 23 
(31.1%), moderate (FEV1 ≥ 50 and < 80% predict-
ed) — 24 (32.4%), severe (FEV1 ≥ 30 and < 50% 
predicted) — 12 (16.2%) and very severe (FEV1 
< 30% predicted) — 3 patients (4.1%), no data 
available — 12 persons (16.2%).
Category A included 25 patients — 33.8%, 
category B — 15 patients (20.3%), category C — 5 
Table 1. Results of spirometry in 62 subjects out of 74 COPD patients performed in 2011
Tabela 1. Wyniki spirometrii w grupie 62 chorych spośród 74 badanych w 2011 roku
Variable Pre-bronchodilator Post-bronchodilator p
FVC (L) 2.9 ± 0.9 2.9 ± 0.8 NS
FVC (% of predicted value) 92.9 ± 22.7 91.1 ± 22.8 NS
FEV1 (L) 1.66 ± 0.7 1.68 ± 0.6 NS
FEV1 (% of predicted value) 66.7 ± 21.5 66.9 ± 20.5 NS
FEV1%FVC (%) 56.4 ± 10.4 56.5 ± 9.7 NS
NS — not significant
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Figure 1. Causes of death in group of 43 subjects
Rycina 1. Przyczyny zgonów w badanej grupie chorych (43 badanych)
patients (6.7%), category D — 17 patients (23%) 
[9, 10]. In 12 subjects (16.2%), COPD category 
has not been established due to lack of correct 
spirometry.
Thirteen patients were hospitalised because 
of COPD exacerbations in the years 2005−2011 
(from 1 to 6 times) (17.6%). The subjects who 
needed hospitalisation had lower FEV1, compared 
to the patients who did not need it (50 ± 17.4% vs 
71.5 ± 18.9% predicted respectively; p = 0.007). 
The study groups did not differ significantly in 
age, BMI, a number of pack-years, severity of 
dyspnoea in the MRC scale.
The most frequent causes of deaths in the 
study groups were cardiovascular diseases (in 
total 21 patients — 48.8% of the study group). 
Heart attack and stroke predominated, having 
caused 16 deaths (8 deaths per illness respec-
tively). Respiratory insufficiency in the course 
of COPD exacerbation was the cause of death in 
10 subjects (23.3%). Neoplastic diseases were 
responsible for 9 deaths (20.9%) (in 7 patients the 
cause of death was concomitant lung cancer, in 
2 — prostate cancer). The remaining deaths were 
caused by exacerbation of renal insufficiency 
(1 patient — 2.325%) and undetermined causes 
(2 patients — 4.65%). The analysis of the causes 
of deaths was illustrated graphically in Figure 1.
Nearly 2/3 subjects died in hospital 
(28 people, 65.1%), the remaining died at home 
(15 individuals — 34.9%). Definitely more deaths 
occurred in men (34 patients — 79.1%), com-
pared with women (9 patients — 20.9%). In the 
initial group of 2005, there were 98 male patients 
(53.6%) and 85 female (46.4%) (p < 0.001). 
Taking into account the place of residence, 
the proportion of deaths was comparable among 
COPD patients living in the city and in the coun-
try [21 (48.8%) and 22 (51.2%) respectively]. The 
patients who died in hospital and home were 
compared in Table 2.
The factor that increased death risk among 
COPD patients was tobacco smoking. Among 
the patients deceased, nearly 90% smoked cig-
arettes (16 current smokers — 37.2% and 22 
former smokers — 51.2%). Solely 5 deceased 
subjects never smoked cigarettes (11.6%). In 
2005, in the group of 183 patients with diag-
nosed COPD, 77 subjects smoked cigarettes 
(42.1%), 58 subjects (31.7%) smoked ciga-
rettes in the past and 48 persons (26.2%) never 
smoked cigarettes (p = 0.0001) [5]. 
More than 75% of the deceased (between 
2006−2011), at the moment of diagnosis were 
at least 60 years of age, and at the moment of 
death, the proportion of patients ≥ 60 years of 
age exceeded 80%. The largest proportion of the 
deceased constituted the subjects between 70 and 
79 years of age (Table 3).
In one third of the deceased, death occurred 
during the first two years after the first exam-
ination (16 subjects, 37.2%). More than half of 
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Table 2.  Comparison of COPD patients died at hospital and at home [5]
Tabela 2.  Porównanie chorych na POChP, którzy zmarli w szpitalu oraz w domu [5]
Variable Hospital deaths
28 chorych/28 subjects
(65.1%)
Home deaths
15 chorych/15 subjects
(34.9%)
p
Age when died (lat/years) 69.6 ± 11 73.9 ± 8.3 NS
BMI (kg/m2) in 2005 24.4 ± 4.2 23.6 ± 2.8 NS
FEV1 post-bronchodilator in 2005 (% predicted) 55.6 ± 17.8 56.8 ± 23.1 NS
Packyears in 2005 (n) 40.9 ± 29.2 42.2 ± 24.3 NS
Males (n/% of males) 22 (64.7%) 12 (35.3%) NS
Females (n/% of females) 6 (66.7%) 3 (33.3%) NS
Town inhabitants (n/%) 12 (64.7%) 9 (35.3%) NS
Village inhabitants (n/%) 16 (72.7%) 6 (27.3%) NS
NS — not significant
Table 3.  Age distribution and death ratio in COPD patients (comparison between 2005 and 2006−2011 years — diagno-
sis of COPD and time of death) [5]
Tabela 3.  Analiza zgonów u chorych na POChP według kategorii wiekowych w chwili rozpoznania choroby (2005 r.) [5] 
oraz śmierci (2006−2011)
Age category 
(years)
COPD Diagnosis (2005)
43 subjects (% of group)
Time of death (2006−2011)
43 subjects 
(% of group)
p
40−49 3 (7%) 1 (2.3%) NS
50−59 7 (16.3%) 7 (16.3%) NS
60−69 8 (18.6%) 8 (18.6%) NS
70−79 22 (51.1%) 21 (48.8%) NS
≥ 80 3 (7%) 6 (14%) NS
NS — not significant
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Figure 2. Percentage of death in consecutive years (2006−2011) in 43 subjects
Rycina 2. Odsetek zgonów w kolejnych latach (2006−2011) w grupie 43 chorych
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Table 4.  Comparison of baseline data (from 2005) age at the time of death in deceased patients according to year of death [5]
Tabela 4.  Charakterystyka chorych zmarłych w latach 2006−2011 (wiek w chwili zgonu oraz pozostałe dane wyjściowe  
z 2005 r.) [5] 
Variable (2005)* 2006
 (n = 2)
2007
 (n = 14)
2008
(n = 9)
2009
(n = 8)
2010
(n = 7)
2011
(n = 3)
p
Age at the time of death (years) 66 ± 8.5 68.7 ± 12.4 69.1 ± 5.7 74.2 ± 11.9 72.6 ± 9.3 80 ± 5.3 NS
*FEV1 post bronchodilator
(% of predicted value)
56.9 ± 5.4 57.8 ± 24.7 63.2 ± 16.4 42.3 ± 14.5 56.4 ± 16.4 66.2 ± 1.4 NS
*Packyears (n) 30.1 ± 13.6 30.4 ± 16.5 44.9 ± 28 56.4 ± 25.7 27.5 ± 20.1 77 ± 45.1 NS
*MRC dyspnea score (points) 3 ± 0 2.6 ± 1.3 2 ± 1 2.5 ± 1.2 2.4 ± 1.5 2 ± 1 NS
NS — not significant
Figure 3. Number and causes of death in years 2006−2011
Rycina 3. Liczba zgonów w zależności od przyczyny w latach 2006−2011
deaths occurred during the first three years of 
follow-up (Fig. 2).
The number of deaths depending on their 
cause between 2006−2011 was illustrated in 
Figure 3.
Characteristics of the patients deceased during 
the consecutive years was presented in Table 4.
During the study, initial data of 2005 of the 
patients who were examined in 2011 (group 1 
— 74 subjects) were compared with data of the 
subjects who died between 2006−2011 (group 
2 — 43 subjects) and data of the patients who 
did not undergo follow-up examination (group 
3 — 66 subjects). COPD patients who died were 
older, had more intensive dyspnoea in the MRC 
scale and lower FEV1, one third of them had 
severe or very severe bronchial obstruction, and 
in 30% of them, COPD category D was diagnosed 
(Table 5) [5].
The evaluation of the group of the patients 
deceased depending on the cause of death (group 
1 — deaths from COPD — 10 subjects; group 
2 — deaths from cardiovascular diseases — 
21 subjects, group 3 — deaths from neoplasms 
— 9 patients; 3 subjects were omitted — 2 with 
undetermined cause of death and one with renal 
insufficiency) revealed significantly lower FEV1 
and significantly higher dyspnoea score  (MRC 
scale) in group 1. The patients who died from 
COPD were older, had lower BMI and a higher 
number of pack-years, compared to groups 2 
and 3 (the differences were not statistically 
significant). Detailed data were included in 
Table 6 [5]. 
Economic status (subjectively assessed by 
patients in 2005) was comparable in the three 
groups (Table 7) [5].
Discussion
Chronic obstructive pulmonary disease (COPD) 
is characterised by a progressive impairment of 
ventilatory reserves, which leads to considerable 
limitations of effort tolerance, frequent exacerba-
tions of the disease and respiratory insufficiency. 
One of the most frequent causes of death in COPD 
patients are disease exacerbations, during which 
respiratory insufficiency occurs or becomes more 
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Table 5.  Comparison of baseline data (from 2005) in alive subjects in 2011 (group 1) and died in years 2006−2011 (group 2)  
and subjects lost to follow-up (group 3) [5]
Tabela 5.  Porównaniu grup chorych (dane wyjściowe z 2005 r.) — pozostających przy życiu w 2011 roku (grupa 1), zmar-
łych w latach 2006-2011 (grupa 2) oraz chorych, których nie udało się zbadać ponownie (grupa 3) [5] 
Variable (2005) Group 1
(n = 74)
Group 2
(n = 43)
Group 3
(n = 66)
p
Age (years) 59.6 ± 9.7* 67.8 ± 9.9*# 60.2 ± 12.5# * 0.001
# 0.003
BMI (kg/m2) 26.1 ± 4.7 24.1 ± 3.8 25.6 ± 4.6 NS
FEV1 post bronchodilator
(% of predicted value)
71.2 ± 17.9* 56 ± 19.5*# 70.5 ± 19.7# * 0.001
# 0.002
Severe and very severe airflow obstruction
(n/%) (FEV1 < 50% pred.)
11 (14.9%)* 14 (32.6%)*# 9 (13.6%)# * 0.008
# 0.005
COPD category D (n/%)XXX 9 (12.2%)* 13 (30.2%)*# 8 (12.1%)# * 0.008
# 0.002
Smokers (n/%) 54 (73%) 38 (88.4%) 43 (67.2%) NS
Packyears (n) 35.2 ± 19.9 41.4 ± 27.1 29.2 ± 26.5 NS
MRC dyspnea score
(points)
1.82 ± 0.99* 2.39 ± 1.19*# 1.5 ± 1.1# * 0.01
# 0.007
MRC score ≥ 2 points (n/%) 39 (52.7%) 30 (69.8%)# 29 (43.9%)# # 0.008
XXXCOPD category was assessed by FEV1 (% of predicted) and MRC score for baseline data from 2005 (CAT questionnaire was not performed and there was no data 
about number of COPD exacerbation during year); NS — not significant
 Table 6.  Comparison of baseline data (from 2005) in deceased patients according to reason of death: group 1 – COPD, 
group 2- cardiovascular diseases, group 3 — neoplasmatic diseases [5]
Tabela 6.  Porównaniu grup chorych (dane wyjściowe z 2005 r.) — na podstawie przyczyny zgonu: grupa 1 — POChP, gru-
pa 2 — choroby sercowo-naczyniowe, 3 — choroby nowotworowe [5] 
Variable (2005) Group 1
(n = 10)
Group 2
(n = 21)
Group 3
(n = 9)
p
Age in the time of death (years) 75.2 ± 13.1 70.7 ± 9.4 68.4 ± 8.9 NS
BMI (kg/m2) 21.1 ± 3.1 24.5 ± 3.5 24.5 ± 2.6 NS
FEV1 post bronchodilator
(% of predicted value)
39.4 ± 16.3* 58.5 ± 18.2*# 68.3 ± 13.5# * 0.04
# 0.005
Smokers (n/%) 9 (90%) 17 (80.9%) 9 (100%) NS
Packyears (n) 41.4 ± 32.9 32.6 ± 16.6 38.4 ± 13.1 NS
MRC dyspnea score (points) 3.5 ± 0.97* 2.1 ± 1.0*# 1.7 ± 1.1# * 0.01
# 0.002
Males (n/% of group) 9 (90%) 14 (66.7%) 8 (88.9%) NS
Town inhabitants (n/% of group) 5 (50%) 10 (47.6%) 6 (66.7%) NS
NS — not significant
intensive [11−14]. Death risk in COPD patients 
is significantly influenced by progression of the 
disease. Among patients with mild and moderate 
form of the disease, who have been observed even 
for 14.5 years since diagnosis, cardiac diseases 
and neoplasms were responsible for 55% of deaths 
[15]. In another study, the risk of premature death 
in patients with severe or moderate form of the 
disease was 2.7 and 1.6 respectively [16]. 
COPD exacerbations were the second most 
frequent cause of deaths in the study group. 
Nearly a quarter of deaths in COPD patients was 
related to respiratory insufficiency in the course 
of disease exacerbation.
Connors et al. [11] were evaluating 1,016 
patients admitted to five hospitals due to COPD 
exacerbation every 6 months. 11% of the subjects 
died during hospitalisation. 20%, 33%, 43% and 
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49% of the patients died 60 days, 180 days, one 
year and 2 years after hospitalisation respec-
tively. The factors that significantly influenced 
an increased death risk in this group of patients 
were as follows: COPD severity, BMI, age, gen-
eral condition of patients prior to exacerbation, 
PaO2, cardiac insufficiency, serum albumin level 
and features of cor pulmonale. In the present 
study, age and COPD progression also impacted 
on death risk.
In the study by the Dutch authors [12], the 
group of 171 COPD patients hospitalised due to 
disease exacerbation has been observed. 8% of 
subjects died in hospital, and 23% during the year 
of follow-up. The factors that had a significantly 
negative impact on prognosis in their study group 
were the following: prolonged use of oral cortico-
steroids, higher PaCO2 and older age (similarly as 
in the present paper). 
Rubinsztajn and Chazan [13] have retrospec-
tively analysed the group of 266 COPD patients 
who were admitted to hospital and died during 
hospitalisation (a mean of age 73 ± 8 years). 
The most frequent cause of death in COPD pa-
tients was as follows: exacerbations of the main 
disease (30%), pneumonia (25%), lung cancer 
(19%), ischaemic heart disease (7%) and cardiac 
insufficiency (5%). Definitely more often than in 
the present paper, the patients died from COPD 
exacerbations and pneumonia (55% vs 23.3%), 
which presumably was related to COPD severity. 
In both studies, the frequent cause of death was 
lung cancer (19% vs 16.3% in the present paper). 
As many as 75% of COPD patients from the 
group of 215 people who had been treated with 
oxygen at home, died during hospitalisation. The 
main causes of death in these subjects were as fol-
lows: severe or chronic respiratory insufficiency 
(38%), cardiac insufficiency (13%), infections of 
the lower airways (11%), pulmonary embolism 
(10%), cardiac arrhythmia (8%) and lung cancer 
(7%) [14]. Definitely more frequently than in the 
present study, the subjects died from respiratory 
insufficiency and respiratory infections (in to-
tal 49% vs 23.5% in the present paper), which 
presumably was related to COPD severity (the 
patients were treated with oxygen at home). 
Quintana et al. [17] prospectively assessed 
deaths of 2,487 COPD patients during hospi-
talisation or the first week after discharge from 
hospital. The examined subjects presented to the 
casualty department due to disease exacerbation. 
Basing on the results obtained, it was found that 
5 factors significantly impacted on the growth of 
death risk in this group of patients (AUC:0.85) 
— age, dyspnoea severity (similarly as in the 
present study), oxygen therapy at home or history 
of non-invasive mechanical ventilation, the use 
of additional respiratory muscles or paradoxical 
breathing and altered consciousness.
In the study carried out by Anthonisen [15], 
the percentage of deaths in the group of 5887 
patients with asymptomatic bronchial obstruc-
tion in the course of COPD was assessed. During 
a 14.5-year follow-up, 731 patients died (33% — 
from lung cancer, 22% — from cardiovascular 
diseases and 7.8% from other diseases of the 
respiratory system). In the present study, cardio-
vascular diseases and lung cancer were also one 
of the most frequent causes of deaths (48.8% and 
16.3% respectively). 
The British authors [18] evaluated the risk 
of death in COPD patients hospitalised due to 
disease exacerbation (meta-analysis of 37 studies 
concerning 189,772 subjects).
At the first stage of the study, “short-term” 
mortality [during hospitalisation and until 90 
days after discharge from hospital (17 studies 
— 184,696 patients, including 13 studies into 
hospital mortality)]. In the whole group, 6,580 
subjects died (3.6%). There were considerable 
differences in mortality between particular stud-
ies — from 1.8% to 20.4%. Prognostic factors that 
influenced the increase in the risk of short-term 
Table 7. Financial status — baseline data (from 2005) in alive subjects in 2011 (group 1) and died in years 2006−2011 
(group 2) and lost subjects (group 3) [5]
Tabela 7. Status ekonomiczny (dane wyjściowe z 2005 r.) – pozostających przy życiu w 2011 roku (grupa 1), zmarłych  
w latach 2006-2011 (grupa 2) oraz chorych nie zbadanych ponownie (grupa 3) [5] 
Financial status (2005) Group 1
(n = 74)
Group 2
(n = 43)
Group 3
(n = 66)
p
Good (% of group) 11 (14.9%) 5 (11.6%) 14 (21.2%) NS
Satisfactory (% of gruop) 58 (78.4%) 36 (83.7%) 44 (66.7%) NS
Bad (% of group) 5 (6.7%) 2 (4.7%) 8 (12.1%) NS
NS — not significant
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mortality were the following: age, male sex, low 
BMI, cardiac insufficiency, renal insufficiency, 
confusion, oxygen therapy at home, oedema of the 
lower extremities, GOLD 4 COPD, cor pulmonale, 
acidosis and elevated troponin (age, male sex and 
advanced COPD were risk factors for death in the 
present study). 
Long-term mortality (the period from 
6 months up to 2 years after hospitalisation) 
was evaluated basing on the results of 8 studies 
(2300 patients). 712 deaths (31.0%) were found 
in this group, and the differences between the 
researches oscillated between 18.8 and 45.4%. 
Prognostic factors that impacted on the increase 
in the risk of long-term mortality were the fol-
lowing: age, low BMI, cardiac insufficiency, 
diabetes mellitus, ischaemic heart disease, neo-
plasms, FEV1, oxygen therapy at home and PaO2 
at hospital admission (in the present study, the 
first and the third cause of death were cardio-
vascular diseases and neoplasms, the patients 
who died also had lower FEV1). 
Mortality rate among COPD patients who 
were admitted to intensive care units was evalu-
ated basing on 12 studies (2,776 patients). In this 
group, 805 patients died (29.0%) (the results of 
particular studies differed considerably, mortality 
oscillated between 17.6% and 48.8%). Higher 
death risk in this group was associated with age, 
lower Glasgow Coma Scale score and pH. 
Limitations of the study
Similarly as in the previous paper [5], pre-
dicted values adopted by the ECSC were used for 
spirometry. Currently, for the European popula-
tion, it is recommended to use predicted values 
as indicated by Falaschetti [19]. Predicted values 
for FEV1/FVC for people ≥ 65 years of age in the 
British authors’ study are higher, compared with 
the norms adopted by the ECSC [8], which could 
be the reason for underdiagnosis of the disease 
in some patients examined in 2005. 
We did not manage to examine or receive in-
formation about 66 patients (36.1% of the whole 
group) from the initial group of 183 patients — 
which adversely impacted on statistical analysis 
in the group examined in 2011. It is unknown how 
many subjects from this subgroup died between 
2006−2011. 
In the group of the patients deceased, there 
was no information about concomitant diseases, 
hospitalisations, number of exacerbations and 
smoking cessation after examinations performed 
in 2005.
COPD category for the data of 2005 was es-
tablished basing on FEV1 and the MRC scale (CAT 
questionnaire was not completed, data concern-
ing the number of COPD exacerbations per year 
were not available).
Conclusions
Follow-up examination performed in COPD 
patients in a single family medicine practice 
institution 6 years after diagnosis of the disease 
revealed a high mortality in the study group 
(43 patients died — 23.5%). 
More than 75% of all deaths were caused 
by cardiovascular diseases (mainly heart attack 
and stroke), COPD exacerbations and lung 
cancer.
The factors that influenced the growth of 
death risk in the study group were as follows: 
age, male sex, severity of dyspnoea (according to 
MRC scale) and more severe forms of the disease 
(severe and very severe bronchial obstruction/
COPD category D). 
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